drugset / Trial / NCT01786902
Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature
RandomizedParallel-groupOpen-labelTreatment
Summary
Growth hormone therapy will improve the height of idiopathic short statured children. DA-3002(Recombinant Human Growth hormone)treated group for 26 weeks, will be compared to non-treatment group in efficacy and safety.
Timeline
- Start
- 2012-02
- Primary completion
- 2014-04
- Completion
- 2014-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DA-3002 | Protein / enzyme biologic | 1.11 iu/kg | Subcutaneous |